Comparison of angioplasty and stenting with cerebral protection versus endarterectomy for treatment of internal carotid artery stenosis in elderly patients

Carotid artery stenting: Identification of risk factors for poor outcomes

“…1,18 In addition, Kastrup et al showed that octogenarians undergoing CAS have higher stroke rates than those undergoing CEA, although this was only a retrospective analysis. 19 In summary, while CAS offers an appealing alternative to CEA, continued analysis of CAS is critical. Recent data from the EVA-3S and SPACE trials has called into question the safety of CAS compared with CEA in patients with symptomatic carotid stenosis, with respect to the risk of stroke, death, and all complications.…”

Target lesion ulceration and arch calcification are associated with increased incidence of carotid stenting-associated ischemic lesions in octogenarians

“…The overall results of our case series and various subgroup analyses have been published previously. 5,17,27,28 All patients were informed about the investigational nature of CAS and gave their written consent. Our CAS protocol and the additional MRI studies were approved by our Institutional Ethics Review Board.…”

“…All CAS procedures were performed using a standardized protocol described in detail recently. 28 Depending on physician preference and commercial availability, four filter-type cerebral protection devices were used in the study. They included Neuroshield in 10 (MedNova, Galway, Ireland), Angioguard in 4 (Cordis, Johnson & Johnson, Minneapolis, Minn), Emboshield in 30 (Abbott, Chicago, Ill), and Filterwire in 18 (Boston Scientific, Natick, Mass).…”

A risk score to predict ischemic lesions after protected carotid artery stenting

“…Details of the carotid stent protocol as well as of the imaging protocol have been described recently [6,11]. In this study, two different self-expandable stents (Smart/Precise (n = 173); Johnson&-Johnson Cordis, Minneapolis, Minn; Boston Scientific Wallstent (n = 3); Boston Scientific, Natick, Mass) and four different filter-type cerebral protection devices (Neuroshield (MedNova, Galway, Ireland); Angioguard (Johnson&Johnson Cordis, Minneapolis, Minn); Emboshield (Abbott, Chicago, Ill), and Filterwire (Boston Scientific, Natick, Mass)) were used.…”